Treatment of the axilla in patients with primary breast cancer and low burden axillary disease: Limitations of the evidence from randomised controlled trials

详细信息    查看全文

• 作者：J.F.R. Robertson^a ; ^{John.robertson@nottingham.ac.uk} ; P.J.J. Herrod^a ; J. Matthew^b ; L.S. Kilburn^c ; C.E. Coles^d ; I. Bradbury^e
• 关键词：Breast cancer ; Axilla ; Surgery
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：110
• 期：Complete
• 页码：74-80
• 全文大小：424 K
• 卷排序：110

文摘

Invasive breast cancer is the second most common cancer worldwide. It is known to metastasise to the regional axillary lymph nodes but there has been debate over what is the best way to stage and treat the axilla in patients presenting with primary breast cancer. Multiple trials over the last two decades have led to a change in practice from routine axillary lymph node dissection to sentinel lymph node biopsy in patients who are clinically lymph node negative preoperatively. This has resulted in new questions regarding subsequent treatment of some patients. This review will critically appraise the evidence on axillary treatment in patients with low burden axillary disease and highlight limitations of relevant randomised controlled trials.